Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

By afschroeder • August 11, 2026

Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, Bardia A, Sedrak MS. Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count? Breast Cancer Res Treat. 2026 Aug 10;218(3):35. doi: 10.1007/s10549-026-08051-y. PMID: 42573832.

Tags: breast cancer, clinical trials, DGSOM Student, Drug approval, Hematology/Oncology, patient-reported outcomes, Publications, Quality of Life, Regulatory science, Tolerability, toxicity

Medical Societies in the United States: History, Purpose, Challenge, and Future Directions

Schiller G, Leer LR. Medical Societies in the United States: History, Purpose, Challenge, and Future Directions. Cureus. 2026 Jul 10;18(7):e112407. doi: 10.7759/cureus.112407. PMID: 42572655; PMCID:[...]

Editorial Expression of Concern: Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, Gera J, Lichtenstein A. Editorial Expression of Concern: Interleukin-6 activates phosphoinositol-3' kinase in[...]

BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma

Singal AG, Agopian VG, Dawson LA, El-Khoueiry A, Finn RS, Halazun K, Heimbach JK, Kelley RK, Kim E, Kulik L, Mehta N, Mendiratta-Lala M, Meyer[...]